Transcatheter Arterial Embolization (TAE) of Cancer-Related Bleeding
Authors:
- Roberto MiniciRoberto Minici
- Giuseppe GuzzardiGGGiuseppe Guzzardi
- Massimo VenturiniMVMassimo Venturini
- Federico FontanaFFFederico Fontana
- Andrea CoppolaACAndrea Coppola
- Marco SpinettaMSMarco Spinetta
- Filippo PiacentinoFPFilippo Piacentino
- Armando PingitoreAPArmando Pingitore
- Raffaele SerraRaffaele Serra
- Davide CostaDavide Costa
- Nicola IelapiNINicola Ielapi
- Pasquale GuerrieroPGPasquale Guerriero
Open Access
Abstract
Background and Objectives: Roughly 10% of cancer patients experience an episode of bleeding. The bleeding severity can range from occasional trivial bleeds to major bleeding. The treatment for the bleeding may vary, depending on the clinical condition and anatomical site, and may include various strategies, among which TAE is a cornerstone of major bleeding management. However, the existing literature on tumor hemorrhages is inconsistent. The objective of this multicenter retrospective cohort study was to evaluate the effectiveness and safety of arterial embolization in the treatment of tumor hemorrhages in patients with solid cancers. Materials and Methods: The data for patients with solid cancers undergoing TAE for the management of tumor hemorrhages from January 2020 to May 2023 were gathered. Results: A total of 92 patients with cancer-related bleeding were treated between January 2020 and May 2023. No bleeding was detected by X-ray angiography (XA) in 12 (13%) cases; therefore, a blind embolization was performed. The most common bleeding site was the liver (21.7%). A total of 66 tumor hemorrhages were spontaneous. The most commonly used embolic agent was polyvinyl alcohol (PVA) particles (30.4%). Technical success was achieved in 82 (89.1%) cases, with an 84.8% clinical success rate related to 14 cases of rebleeding. Proximal embolization was performed for 19 (20.7%) patients. Complications were recorded for 10 (10.9%) patients. The 30-day bleeding-related mortality was 15.2%. The technical success, clinical success, proximal embolization rate, and 30-day rebleeding were worse in the subset of patients undergoing TAE with coils. Conclusions: Transcatheter arterial embolization (TAE) represents a viable and potentially life-saving therapeutic approach in the management of tumor hemorrhages, demonstrating a notable effectiveness and safety. The TAE of bleeding tumors using coils resulted in a higher rate of non-superselective proximal embolization, with a trend toward lower clinical success rates and higher rebleeding episodes.Keywords
This publication has 104 references indexed in Scilit:
- Palliative Procedures in Lung CancerSeminars in Interventional Radiology, 2013
- Early Outcomes of Empiric Embolization of Tumor-related Gastrointestinal Hemorrhage in Patients with Advanced MalignancyJournal of Vascular and Interventional Radiology, 2012
- Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapyRadiation Oncology, 2012
- Evaluation of a Liquid Embolization Agent (Onyx) for Transcatheter Embolization for Renal Vascular LesionsRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2009
- An Overview of Embolic AgentsSeminars in Interventional Radiology, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients’ experiences from a single medical centerSupportive Care in Cancer, 2007
- Outcome after Emergency Surgery in Gastric Cancer Patients with Free Perforation or Severe BleedingDigestive Surgery, 2006
- Nonvariceal Upper Gastrointestinal Bleeding: Epidemiology and DiagnosisGastroenterology Clinics of North America, 2005
- Management of Bleeding in Patients with Advanced CancerThe Oncologist, 2004